Furthermore, tissue-based PD-L1 assessment does not recapitulate the overall tumor heterogeneity that may explain the common discordant clinical responses of patients to immunotherapy even in presence of high PD-L1 positivity. The gene discussed is CD274; the disease is neoplasm.